Trials / Completed
CompletedNCT00109564
A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)
A Safety and Efficacy Study of TC-1734-112 in Subjects With Age Associated Memory Impairment (AAMI)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 174 (planned)
- Sponsor
- Targacept Inc. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI). AAMI is characterized as cognitive impairment including memory loss and poor concentration associated with aging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ispronicline (nicotinic acetylcholine receptor agonist) |
Timeline
- Start date
- 2005-01-01
- Completion
- 2005-10-01
- First posted
- 2005-04-29
- Last updated
- 2008-07-18
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00109564. Inclusion in this directory is not an endorsement.